Luís Felipe Leite

Luís Felipe Leite

Auto-generated profile, based on publicly available information

Luís Felipe Leite

Universidade Federal Fluminense, Brasil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
JSJesse Lopes da Silva
Jesse Lopes da Silva
LOLeandro Jonata de Carvalho Oliveira
Leandro Jonata de Carvalho Oliveira
CRCristiano Augusto Andrade de Resende
Cristiano Augusto Andrade de Resende
TRTomas Reinert
Tomas Reinert
LALucas Zanetti de Albuquerque
Lucas Zanetti de Albuquerque
MMMax Senna Mano
Max Senna Mano
This narrative review explores the mechanisms underlying resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor (HR)-positive metastatic breast cancer (MBC), a critical challenge in contemporary oncology. Despite the proven efficacy of CDK4/6i in improving clinical outcomes, both intrinsic and acquired resistance remain substantial challenges. We discuss clinical data that underscore pivotal molecular alterations associated with resistance, including mutations in the Retinoblastoma gene ( RB1 ), germline variants, aberrations in the PIK3CA gene that activate the phosphatidylinositol 3-kinase/protein kinase B (AKT)/mammalian target of rapamycin signaling cascade, and modifications in fibroblast growth factor receptor signaling. Additional resistance mechanisms—such as the loss of the FAT1 tumor suppressor gene and the dysregulation of cell cycle regulators like cyclin E and CDK2 —are also explored. The role of circulating tumor DNA analysis in tracking genomic changes during therapy is also considered. Furthermore, the review assesses emerging therapeutic strategies, particularly combination therapies that target alternative pathways to counteract resistance mechanisms. By synthesizing current evidence and providing actionable insights, this review aims to enhance our understanding of endocrine resistance mechanisms among clinical oncologists and gives them some future perspectives to expand strategies to overcome this challenge.

1 December 2025 in Cancer Research Communications
Verified
Journal Article
Open access
LLLuís Felipe Leite
Luís Felipe Leite
LCLucas Diniz da Conceição
Lucas Diniz da Conceição
ESErick F. Saldanha
Erick F. Saldanha
SMSamuel Menezes
Samuel Menezes
AMAndreia C. De Melo
Andreia C. De Melo
VLVLADMIR Cláudio CORDEIRO DE LIMA
VLADMIR Cláudio CORDEIRO DE LIMA
Cancer is a leading cause of death in Latin America and the Caribbean (LAC), and up-to-date estimates are essential to guide cancer policy. Using GLOBOCAN 2022 data, we analyzed cancer incidence and mortality across 32 LAC countries, calculated age-standardized rates, and assessed early-onset cancer (diagnosed at ages 15–50 years). Mortality-to-incidence ratios were used as a proxy for survival, joinpoint regression estimated annual percent change, and linear regression evaluated correlation between the Human Development Index and cancer indicators. In 2022, LAC recorded 1,551,060 new cancer cases (age-standardized incidence rate, 186.6 per 100,000) and 749,242 deaths (age-standardized mortality rate, 85.2 per 100,000). Prostate and breast cancers were the most common malignancies, whereas lung and breast cancers caused the highest mortality. Mortality declined for prostate cancer [annual percent change, −1.52; 95% confidence interval (CI), −1.80 to −1.24] and male lung cancer (−2.50; 95% CI, −2.68 to −2.33) but increased for female lung (+1.88; 95% CI, 1.71–2.05) and colorectal cancer (+2.48; 95% CI, 2.30–2.67). Human Development Index showed an inverse correlation with mortality-to-incidence ratio (P < 0.001), suggesting improved survival with higher development. Early-onset cancers represented 17% of new cases and 11% of deaths. These findings reveal a growing cancer burden and that persistent disparities in cancer epidemiology persist across LAC, highlighting the urgent need for targeted cancer control strategies and regional cancer control plans. Significance: These findings highlight the urgent need for equity-focused cancer control policies, improved early detection, and expanded access to essential cancer care in the region.

16 December 2025 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
IBIsabella R. Buonopane
Isabella R. Buonopane
ESErick F. Saldanha
Erick F. Saldanha
JMJúnior Samuel Alonso de Menezes
Júnior Samuel Alonso de Menezes
LCLucas Diniz da Conceição
Lucas Diniz da Conceição
CRCamila Mariana de Paiva Reis
Camila Mariana de Paiva Reis
Tiago Biachi de CastriaTiago Biachi de Castria
Tiago Biachi de Castria

13 August 2025 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
MNMariana Macambira Noronha
Mariana Macambira Noronha
LSLuís Felipe Leite da Silva
Luís Felipe Leite da Silva
LALuiz Felipe Costa de Almeida
Luiz Felipe Costa de Almeida
PPPedro Passos
Pedro Passos
PRPedro Cotta Abrahão Reis
Pedro Cotta Abrahão Reis
ESErick F. Saldanha
Erick F. Saldanha
Metastatic uveal melanoma (mUM) is a rare disease associated with poor prognosis and limited therapeutic options. Recent studies showed that detecting ctDNA is feasible and can aid treatment decisions for patients with mUM. We systematically searched PubMed, EMBASE, and Cochrane databases for eligible studies published up to May 2025 that included patients with mUM and reported data on the association between ctDNA and survival outcomes (OS and PFS). Statistical analyses were performed using Review Manager 5.4 software. Of the initial 450 records, seven studies met eligibility, including 518 patients with mUM. At baseline, ctDNA positivity was associated with significantly worse PFS (HR 2.34; 95% CI 1.56–3.51; p < 0.01; I2 = 0%) and OS (HR 3.32; 95% CI 2.09–5.29; p < 0.01; I2 = 48%). In patients treated with tebentafusp, ctDNA clearance was associated with superior OS (HR 0.19; 95% CI 0.07–0.49; p < 0.01; I2 = 46%) and any decrease in ctDNA was associated with better OS (HR 0.42; 95% CI 0.22–0.80; p < 0.01; I2 = 0%). This meta‐analysis underscores ctDNA as a potential predictor of worse survival in patients with mUM, highlighting its potential to refine risk stratification and guide treatment strategies.Trial Registration: International Prospective Register of Systematic Reviews (PROSPERO): CRD42025638076

12 February 2026 in ESMO Open
Verified
Journal Article
Open access
WSWallace Schwengber
Wallace Schwengber
RPR.A. Pereira
R.A. Pereira
LSL.F. Leite da Silva
L.F. Leite da Silva
MTM. Tumelero
M. Tumelero
GLG. Lenz
G. Lenz
MSM.B. Sonbol
M.B. Sonbol
Early studies indicate that neoadjuvant immune checkpoint inhibitors (ICIs) induce high rates of tumor regression in localized deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) gastric and gastroesophageal junction (GEJ) cancers, raising interest in nonoperative management (NOM). Most available data, however, come from small, nonrandomized cohorts. A systematic synthesis was undertaken to better characterize efficacy and safety outcomes. A systematic search of PubMed, EMBASE, Scopus, Web of Science, and Cochrane Reviews was conducted from inception through June 2025 for prospective or retrospective studies of neoadjuvant ICIs in localized dMMR/MSI-H gastric or GEJ cancers reporting at least one prespecified outcome. Two reviewers independently extracted data and assessed study quality according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Pooled estimates were calculated using a DerSimonian and Laird random-effects model, and NOM outcomes were qualitatively summarized. Twenty studies (396 patients) met inclusion criteria; three used dual ICI therapy, and the remainder used ICI alone or with chemotherapy. Overall, 320 patients (81.0%) underwent surgical resection. The pooled pathologic complete response (pCR) rate was 41.9% [95% confidence interval (CI) 33.2% to 51.1%], clinical complete response 63.8% (95% CI 45.6% to 78.8%), major pathologic response 64.2% (95% CI 49.1% to 76.9%), and grade 3-4 immune-related adverse events 6.7% (95% CI 1.7% to 13.8%). pCR was higher with treatment duration ≥3 months compared with <3 months [50.2% (95% CI 42.3% to 58.7%) versus 28.4% (95% CI 18.9% to 40.2%), χ2 = 8.84, P = 0.003]. Forty-four patients were managed nonoperatively, with two early local regrowths at median follow-up ranging from 11.5 to 28 months. Neoadjuvant ICIs are associated with favorable efficacy and safety in localized dMMR/MSI-H gastric and GEJ cancers. Longer neoadjuvant exposure (≥3 months) may improve pCR rates. Larger prospective studies are needed to define optimal treatment duration and the role of organ-preserving strategies such as NOM.

6 May 2025 in BMJ Oncology
Verified
Journal Article
Open access
PDF file
LLLuís Felipe Leite
Luís Felipe Leite
LALuiz F Costa de Almeida
Luiz F Costa de Almeida
LCLucas Diniz da Conceição
Lucas Diniz da Conceição
MNMariana Macambira Noronha
Mariana Macambira Noronha
MBMarcos Belotto
Marcos Belotto
Bishal GyawaliBishal Gyawali
Bishal Gyawali
Objective: Disease-free survival (DFS) is frequently used as the primary endpoint in trials of adjuvant and neoadjuvant therapies for early-stage pancreatic cancer (PC), but its validity as a surrogate for overall survival (OS) remains uncertain. This study evaluates the strength and consistency of DFS as a surrogate for OS in early-stage PC trials. Methods and analysis: This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Trials of early-stage PC involving drug therapy were identified through PubMed, Embase and Cochrane CENTRAL databases, and data on DFS and OS with HR and CIs were extracted. Trial-level surrogacy of DFS for OS was assessed using weighted linear regression, calculating the coefficient of determination (R²) and surrogate threshold effect (STE). Results: 29 trials involving 6777 patients were included. In adjuvant trials, HR of DFS strongly correlated with HR of OS (R²=0.70) at trial-level, with the STE of 0.94 indicating the maximum DFS HR beyond which OS benefit was unlikely. The correlation strength differed between phase III (R²=0.71) versus phase II (R²=0.67) trials. This correlation was stronger in trials including radiation therapy (R²=0.81) and trials in the neoadjuvant setting (R²=0.90). No trial in our study was a registration trial of a new molecule and all involved chemotherapy. Conclusion: Treatment effects on DFS had a strong correlation with treatment effects on OS, making DFS a potential surrogate endpoint for OS in early-stage PC trials of cytotoxic chemotherapies, but its use in registration trials requires careful consideration due to variability across treatment settings and trial designs. PROSPERO registration number: CRD42024595441.